| Bioactivity | Vorsetuzumab mafodotin (SGN-75) is an Auristatin-based anti-CD70 antibody-drug conjugate (ADC). Vorsetuzumab mafodotin consists of a humanized monoclonal antibody, Vorsetuzumab and an ADC cytotoxin MMAF. Vorsetuzumab mafodotin has antineoplastic activity[1]. |
| Invitro | Vorsetuzumab mafodotin（SGN-75；0.01-10000 ng/mL；持续 96 小时）诱导剂量依赖性细胞毒性，IC50 为 29 ng/mL[1]。 Cell Cytotoxicity Assay[1] Cell Line: |
| In Vivo | Vorsetuzumab mafodotin（SGN-75；3mg/kg；四次腹膜内注射，间隔 4 天）显着减小中位肿瘤体积并延缓肿瘤生长[1]。 Animal Model: |
| Name | Vorsetuzumab mafodotin |
| CAS | 1165741-01-4 |
| Molar Mass | 150 (kDa) |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. M C Ryan, et al. Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75. Br J Cancer. 2010 Aug 24;103(5):676-84. |
Vorsetuzumab mafodotin
CAS: 1165741-01-4 F: W: 150 (kDa)
Vorsetuzumab mafodotin (SGN-75) is an Auristatin-based anti-CD70 antibody-drug conjugate (ADC). Vorsetuzumab mafodotin c
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.